Application No.: 09/687,864 Docket No.: 30906/41457UTL

Response to Office Action Dated 9/20/05

Amendments to the Claims

1-14. Canceled

15. (Currently amended) An antigenic polypeptide comprising an antigen domain and a receptor-binding domain, said antigen domain comprising HIV-1 gp160 or a portion thereof and said receptor-binding domain comprising a CD40-binding polypeptide,

wherein the CD40-binding polypeptide is selected from the group consisting of CD154, extracellular domains of CD154 or a portion of the extracellular domain which retains the ability to bind CD40, anti-CD40 scFv, and single antibody variable regions that bind CD40.

- 16. (Previously presented) An antigenic polypeptide of claim 15, wherein said receptor-binding domain comprises at least a portion of an immunoglobulin.
- 17. (Previously presented) An antigenic polypeptide of claim 15, wherein said receptor-binding domain comprises a single chain Fv.
- 18. (Previously presented) An antigenic polypeptide of claim 15, wherein said CD-40 binding protein comprises CD 154 or a portion of CD 154.
- 19. (Previously presented) An antigenic polypeptide of claim 15, comprising an amino acid sequence according to any one of SEQ ID NO: 20, 21, 22, 23, 24, 25, 26, or 27.
- 20. (Previously presented) An antigenic polypeptide_of claim 15, wherein said CD40-binding polypeptide comprises a camelid immunoglobulin variable region.
- 21. (Currently Amended) An antigenic polypeptide of claim 15, wherein said receptor-binding domain is capable of binding CD40 and one or more additional receptors.
 - 22. (Canceled)
- 23. (Previously presented) An antigenic polypeptide of claim 15, encoded by a polynucleotide comprising a sequence according to any one of SEQ ID NO: 12, 13, 14, 15, 16, 17, 18, or 19.

Application No.: 09/687,864 Docket No.: 30906/41457UTL

Response to Office Action Dated 9/20/05

24. (Previously presented) An antigenic polypeptide of claim 23, wherein said polynucleotide is operably linked to a DNA plasmid.

25. (Canceled)

26. (Previously presented) An antigenic polypeptide of claim 15 that is capable of eliciting an immune response in an animal.

27. (Previously presented) An antigenic polypeptide of claim 15 that is produced in an animal.

28. (Previously presented) An antigenic polypeptide comprising an antigen domain and a receptor-binding domain, said antigen domain comprising HIV-1 gp160 or a portion of HIV-1 gp160, said receptor-binding domain comprising at least a portion of a CD 154 polypeptide capable of binding to CD40.

29. (Previously presented) An antigenic polypeptide of claim 28 encoded by a polynucleotide comprising a sequence according to any one of SEQ ID NO: 12, 13, 14, 15, 16, 17, 18, or 19.

30. (Previously presented) An antigenic polypeptide of claim 28 wherein said antigenic polypeptide comprises an amino acid sequence according to any one of SEQ ID NO: 20, 21, 22, 23, 24, 25, 26, or 27.

31-33. (Canceled)